PRMT5 and cancer: Protein arginine methyltransferase 5 (PRMT5) inhibitors significantly downregulate the expression levels of various DDR‐related genes in cancer cells, thereby increasing the sensitivity of cancer cells to chemotherapeutic agents [83].